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Abstract
Individualised information in substance misuse treatment complements standardised
outcome measures. However, few studies investigate the use of individualised measures
and their robustness in terms of quantifying outcomes. In this study, we analysed the
psychometrics and feasibility of two individualised outcome measures (PQ and
PSYCHLOPS). We followed a cross-sectional methodology, administering the
individualised measures and three additional standardised measures (TOP, a measure of
psychological health within addiction services; PHQ-9; CORE-OM) to a sample of 93
patients entering substance misuse treatment in four clinical services. The results showed
high levels of patient acceptability of the two individualised measures (response rates >
95%). The internal reliability was good for both PQ and PSYCHLOPS (Cronbach’s
alpha, .79 and .72, respectively). Convergent validity of PQ with standardised measures
was weak: Pearson’s r values for TOP (psychological health), PHQ-9 and CORE-OM
were .21, .22 and .27, respectively. In contrast, convergent validity of PSYCHLOPS was
moderate: r = .40, .39 and .50, respectively. Convergence between PQ and PSYCHLOPS
was weak (r = .28). Experience of previous treatment episodes was associated with higher
PQ and PSYCHLOPS scores; PSYCHLOPS but not PQ scores were higher among those
opting to complete the questionnaires in written rather than verbal format. Our findings
demonstrated that PQ and PSYCHLOPS are reliable and feasible individualised outcome
measures for use in substance misuse treatment units, although the lack of strong
convergent validity indicates that they may be measuring different underlying constructs.
Optimal outcome measurement may involve combining individualised and standardised
measures.
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The evaluation of treatment outcomes has, until recently, been dominated by a nomothetic
approach. However, a growing body of expert opinion has recommended that idiographic, or
individualised, information should also be used for outcome measurement purposes (Ashworth
et al. 2019; Alves et al. 2015; Neale and Strang 2015). Combining nomothetic and idiographic
approaches has been described as an ‘optimal way of understanding and measuring patient
reported outcomes of addiction and its related constructs’ (Neale and Strang 2015, p. 1216).
However, little is known about the psychometric properties of individualised outcome mea-
sures when tested within the context of substance misuse treatment services and the validity of
self-reported outcomes in this setting.
Broadly speaking, outcome measures aim to quantify changes that occur in a patient’s
clinical status over a course of treatment. The commonest strategy involves the use of
standardised outcome measures, based on pre-set questions administered to a group of patients.
The standardised structure of these measures allows for mechanisation of the outcome
measurement process, since all individuals are presented with the same pre-determined
questions (OECD 2013). The generation of large-scale data from standardised instruments
has given these measures a golden status in the field of outcome evaluation (Evans et al. 2000).
In recent years, individualised outcome measures have gained ground in health care
(Fitzpatrick et al. 1998) for a number of reasons. First, they provide patients with an
opportunity to indicate items to evaluate the outcome of their treatment (Barkham 2016);
second, they allow patients to rate the intensity or level of distress caused by their own
problem, corresponding to their priorities (Elliott et al. 2016; Sales and Alves 2012, 2016);
third, they have a greater sensitivity to clinical change than standardised outcome measures
(Ashworth et al. 2009; Elliott et al. 2016); fourth, they are likely to capture information
overlooked by standardised measures (Alves et al. 2018); and fifth, patients value the
opportunity to define and express their own range of concerns (Alves et al. 2016); sixth, there
is recognition of the clinical utility of PQ and PSYCHLOPS, since both contain items of high
relevance for patients (Ashworth et al. 2005; Sales et al. 2007); and seventh, therapist
satisfaction has also been reported for both measures for a variety of clinical tasks including
outcome assessment (Sales et al. 2007; Sales and Alves 2012).
For Lambert and Hawkins (2004), to be appropriate, outcome measures must be ‘psycho-
metrically strong, applicable and practical’ (p. 493). A growing body of literature has explored
these properties among individualised outcome measures. These studies have focused mostly
on the Simplified Personal Questionnaire (PQ; Elliott et al. 2016) and the Psychological
Outcome Profiles (PSYCHLOPS; Ashworth et al. 2004). PQ and PSYCHLOPS are
individualised measures targeting general psychological distress, based on items generated
by patients, and widely used in mental health care (Sales and Alves 2016).
Regarding psychometric properties, both PQ and PSYCHLOPS have demonstrated reli-
ability and validity within a range of mental health settings (e.g. university counselling units,
mental health primary care) (Ashworth et al. 2009; Elliott et al. 2016). However, further
studies to extend psychometric testing are required to diminish scepticism about the use of
individualised measures (Elliott et al. 2016).
Substance misuse treatment is one of the fields where individualised measures have been
little explored. In this client group, outcome measurement tends to focus on specific drug-
related issues, as well as psychosocial variables, including general psychological distress and
specific problems such as depression or suicidal thoughts (Darke et al. 2007; Gossop et al.
2003; Jones et al. 2009; Wanigaratne et al. 2005). Outcomes tend to be assessed with
standardised instruments and it is unknown whether individualised outcome measures in this
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context are feasible and psychometrically robust for outcome measurement purposes, as
observed in other fields (Alves et al. 2015).
The first recorded use of PQ and PSYCHLOPS in a substance misuse treatment setting was
in Portugal in 2013 and has formed the basis of a longer term study which includes the present
study (Alves et al. 2013). Preliminary findings show that patients value these measures for
being easy to understand; helping them to reflect about personal difficulties; providing them
with freedom to talk about problems, related or not to substance misuse; and making them ‘feel
like normal people’ (Alves et al. 2016). As a downside, patients reported that the level of self-
exposure required by these instruments was sometimes uncomfortable and might contribute to
non-completion (Alves et al. 2016). This project also revealed that PQ and PSYCHLOPS elicit
problems overlooked by standardised measures (Alves et al. 2018). For instance, more than
two-thirds of themes indicated by patients in these individualised measures were absent from
the Treatment Outcomes Profile (TOP; Marsden et al. 2008), including problems such as
‘money worries’ and ‘self-image/self-worth’ (Alves et al. 2018). The present study builds on
these findings by exploring the feasibility of PQ and PSYCHLOPS, as well as their psycho-
metric properties in this sample.
Study Rationale
The current study focussed mainly on the feasibility and psychometric properties of PQ and
PSYCHLOPS and standardised comparators. Additionally, we explored potential factors that
may influence PQ and PSYCHLOPS scores (e.g. socio-demographic, substance misuse,
treatment history and other variables of interest), to gain further knowledge about the psycho-
metric value of these instruments. We also aimed to contrast the scorings obtained with PQ and
PSYCHLOPS, since both are individualised measures albeit with different characteristics (e.g.
mode of administration). To our knowledge, this is the first study to explore these three
questions within the context of substance misuse services.
Methods
This was a cross-sectional study with a sample of adult patients entering treatment in four
services for drug and alcohol substance misuse in Portugal, between July 2013 and May 2015.
Approval was granted by the Committee for Health of Lisbon and surrounding areas
(ARSLVT, Ref. 8251/CES/2012).
Participants
The sample comprised of patients aged 18 years and older, who were starting a treatment
episode (i.e. first episode or treatment of a relapse) and were fluent in Portuguese. We
excluded patients who were not motivated to participate or were too distressed to complete
the evaluation protocol. This decision was made by researchers in consultation with the
administrative/clinical staff available. We calculated our proposed sample size based on
previously reported alpha scores of .80 for PSYCHLOPS, with 114 patients, and .86 for
PQ, with 72 patients (Ashworth et al. 2009; Elliott et al. 2016). Based on these findings, we
sought to recruit a sample of 100 patients. Of the 102 individuals who met the inclusion
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criteria, 94 (92%) consented to participate. One was excluded because of non-completion of
PQ and PSYCHLOPS, resulting in a final sample of 93 patients.
Instruments
Simplified Personal Questionnaire (PQ; Elliott et al. 2016) This is a semi-structured
interview-based individualised outcome measure that asks patients to describe the main
problem(s) that resulted in them seeking treatment. The intention is to prompt patients to
elicit an unlimited number of personalised items, without any limitations on subject,
where each item represents a unique problem of the patient expressed in their own
words. After the item generation process, the patient is asked to rate each item/
problem according to how much it troubled him/her over the last week using a 7-point
scale (ranging from ‘1 = not at all’ to ‘7 = maximum possible’) and for how long the
problem has been of concern, also recorded on a 7-point rating scale (from ‘1 = less than
1 month’ to ‘7 = more than 10 years’). PQ total score corresponds to the sum of the
scorings of all items elicited by each patient with a possible score range depending on
the number of items reported with no ceiling on the permissible number of items (e.g. for
two items reported, the score will range from 2 to 14).
Psychological Outcome Profiles (PSYCHLOPS; Ashworth et al. 2004) This is a self-report
individualised measure in which patients are invited to write down one or two
personalised problems in free-text boxes, in response to the statements, “choose the
problem that troubles you most” (P1) and “choose another problem that troubles you”
(P2). Each problem is rated according to how much it has affected him/her over the last
week, on a 6-point scale (from ‘0 = not at all affected’ to ‘5 = severely affected’), and for
duration on a 5-point scale (from ‘0 = under one month’ to ‘4 = over five years’).
PSYCHLOPS includes a third personalised item prompted by the statement, “choose one
thing that is hard to do because of your problem or problems” (functioning), also rated
on a 6-point scale (from ‘0 = not at all hard’ to ‘5 = very hard’). There is a final
standardised item where patients are asked to rate the question, “how have you felt in
yourself this last week” on a 6-point scale (from ‘0 = very good’ to ‘5 = very bad’) (well-
being). PSYCHLOPS total score corresponds to the sum of the scores of the two
problems, the functioning and well-being items. In case P2 is missing, the score of P1
should be doubled (‘pro-rated’); if either P1 or the functioning or well-being items are
missing, the total score cannot be computed. Scores range from 0 to 20.
Clinical Outcomes in Routine Evaluation–Outcome Measure (CORE-OM; Evans et al.
2002) This is a self-report standardised 34-item tool to assess the level of psychological
distress in four domains: problems (depression, anxiety, physical problems and trauma),
functioning (general daily functioning, relationships), subjective well-being (feelings about
self and optimism about the future) and risk behaviours (risk to self and to others). All items
are scored on a 5-point scale (from ‘0 = not at all’ to ‘4 = most or all the time’, or the opposite,
for reversed items) based on the number of times that each item was experienced by patients in
the previous week. CORE-OM total score corresponds to the sum of the 34 items and ranges
from 0 to 136. If more than three items are missing, the total score cannot be computed.
Regarding the four domains, if more than one item is missing from problems and well-being,
these total scores cannot be computed as well.
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Patient Health Questionnaire-9 (PHQ-9; Kroenke et al. 2001) This is a self-report
standardised 9-item questionnaire to evaluate depression. In this measure, patients are asked
to score each item in a 4-point scale (from ‘0 = not at all’ to ‘3 = nearly every day’), according
to the frequency that each problem troubled the patient in the last 2 weeks. PHQ-9 total score
corresponds to the sum of the 9 items, ranging from 0 to 27.
Treatment Outcomes Profile (TOP; Marsden et al. 2008) This is a standardised questionnaire
orally administered by researchers, in an interview, that includes 20 questions about key aspects
of substancemisuse treatment: substance use, injecting risk behaviour, crime, health and quality
of life. In TOP, items are rated in number of days, yes/no questions and scaling items ranging
from 1 to 20 points. Three items within TOP can be used for comparison with other psycho-
metric instruments: psychological health, physical health and quality of life scales.
Procedure
Researchers invited patients attending the treatment centres to take part in the study prior to
commencing treatment. Written consent was obtained and participants completed the evalu-
ation protocol immediately prior to the first treatment session.
Patients were presented with the evaluation protocol containing the five outcome measures,
followed by a socio-demographic and treatment history form. Patients were offered assistance
if they needed additional help with self-completion questionnaires. We randomised the order
in which instruments were presented to patients, to control for sequencing effects and avoid
bias arising from patient responses in one instrument influencing responses in a subsequent
instrument. The presentation order of TOP was not randomised. TOP was invariably presented
at the end of the protocol because it focusses specifically on drug-related topics and little or no
influence was expected.
Data Analysis
Feasibility We focussed on three main parameters to evaluate the feasibility of individualised
measures: administration duration in minutes (note: we opted for timing the entire protocol,
instead of each measure separately, to interfere as little as possible with the evaluation process,
considering that only one researcher was present in the room); acceptability, i.e. proportion of
patients who completed each instrument; and the preferred mode of administration, i.e.
proportion of patients who were able to complete by self-report or who required assistance
from a research administrator (upon patient’s request).
Descriptive Analyses of PQ and PSYCHLOPS PQ and PSYCHLOPS data were analysed in
terms of mean number of patient-reported items, mean severity of distress and mean problem
duration since onset. Because of the unpredictability of the number of patient-reported items in
PQ, overall mean severity and duration were based on the individual PQ score mean for each
patient. Data on problem duration were also recorded based on the longest reported duration in
PQ and PSYCHLOPS.
Internal Reliability of PQ and PSYCHLOPS For PQ, we computed consecutive Cronbach’s
alpha values, starting with 2 items (PQ item #1 and PQ #2) and then consecutively calculating
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new alphas by adding the next PQ item (one at a time) to the calculation. A total of four alphas
were computed until the last item mentioned by at least 15 patients (i.e. PQ item #5) was
added. The mean (and respective standard deviation) of the alpha for PQ represents the mean
of the four alphas that resulted from this procedure, following the procedure described by
Elliott et al. (2016). For PSYCHLOPS, we opted for two alpha values, one for the three
individualised items and one for the total score.
Convergent Validity of PQ and PSYCHLOPS Correlations between instrument scores were
calculated using Pearson’s r. The mean scores of PQ and PSYCHLOPS were correlated
with CORE-OM, PHQ-9 and TOP (psychological health, physical health and quality of
life scale items). As in Elliott et al. (2016), we expected moderate to strong correlations
between individualised and standardised measures. Unlike CORE-OM and PHQ-9, the
scale items of TOP have their scores reversed (i.e. 0 = very bad and 20 = very good) in
contrast to PQ and PSYCHLOPS; hence, convergent validity would be indicated by a
negative correlation.
In addition to feasibility and psychometrics of the individualised measures, we also
explored the association between PQ and PSYCHLOPS scores with socio-demographic
information, substance misuse and treatment history variables. The objective of these further
analyses was to extend our knowledge about the scoring outcome data generated by
individualised instruments, as well as investigating potential variables that might influence
data interpretation. PQ and PSYCHLOPS scores were also contrasted according to their mode
of administration (interview vs. self-report) and order of instrument administration (severity of
scores in the first and second individualised completed by patients). For binary variables, the
Student’s t test was used; for nominal variables with more than two values, one-way ANOVAs
(followed by Bonferroni post hoc analyses) were computed; for continuous data, Pearson’s
correlation was calculated.
All analyses were conducted in IBM SPSS Statistics 22.
Results
The 93 patients who participated in our study consisted of a higher proportion of men (59%);
the mean age was 43 years (SD = 11). Tables 1, 2 and 3 show further characteristics of the
sample, as well as their substance use and treatment history, respectively.
Feasibility of Individualised vs. Standardised Outcome Measures
The mean time required for completion of the five instruments within the evaluation protocol
was 30.1 min (SD = 11.4, range 10–61 min). Regarding the acceptability, the number and
proportion of patients who responded to each instrument were as follows: PQ, 92 (99%);
PSYCHLOPS, 88 (95%); CORE-OM, 92 (99%); PHQ-9, 93 (100%); TOP, 90 (97%).
Concerning the mode of administration, PQ and TOP were delivered in an interview-based
format, as required by their instructions. The self-report tools often required research admin-
istrator completion. PSYCHLOPS was administered orally to 37 (41%) patients, CORE-OM
to 36 (40%) patients and PHQ-9 to 35 (39%) patients. Patients requested assistance because of
literacy issues, self-reported anxiety and poor sight.
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Descriptive Analyses of PQ and PSYCHLOPS Mean Scores
The mean number of items in PQ was 2.9 (SD = 2.1), range 1 to 12. The mean severity score
for PQ items was 5.3 (SD = 1.7). Eighty-two (89%) patients had mean PQ severity scores
above the clinical cutoff value of 3.25 points, as defined in Elliott et al. (2016). Problems
described in PQ had lasted, on average, 1 to 2 years; however, the longest duration problem
was 3 to 5 years.
For PSYCHLOPS, the mean number of patient-generated items (P1 + P2 + function) was
2.3 (SD = .8), range 0 to 3 items. The mean item severity scores were as follows: problems, 7.1
(SD = 2.9, range 0–10); function, 3.4 (SD = 1.7, range 0–5); well-being, 2.3 (SD = 1.8). The
mean total PSYCHLOPS score was 13.8 (SD = 4.9, range 0–20). Even though we collected 88
PSYCHLOPS, the total score could only be computed for 58 (66%) because of insufficient
data (i.e. two problems missing and/or function, and/or well-being item missing). The duration
Table 1 Patient characteristics (N = 93)
Variable Description N (%)
Relationship status Single 45 (48.4%)
Married/cohabiting 19 (20.4)
Divorced/separated 29 (31.2%)
Educational level Illiterate 3 (3.2%)
Literate, but not completed primary school 1 (1.1%)
Basic school (years 1–9) 64 (68.8%)
Secondary school (years 10–12) 15 (16.1%)
University (years > 12) 10 (10.8%)
Employment status Paid work (full-time/part-time) 26 (28.0%)
Unemployed 52 (55.9%)
Retired 8 (8.6%)
Other (e.g. housewife/househusband) 7 (7.5%)
Accommodation status Rented/owned house 84 (90.3%)
Temporary accommodation (e.g. guesthouse) 1 (1.1%)
Homeless 2 (2.2%)
Shared supported accommodation (e.g. community shelters) 6 (6.5%)
Table 2 Substance misuse—age of onset and usage in the last 12 months (N = 93)
Type of substance Years: mean (standard deviation) n (%)
Alcohol Age of onset 16.5 (7.7) 58 (62.4%)
Used in the last 12 months (yes)
Heroin Age of onset 20.2 (6.7) 10 (10.8%)
Used in the last 12 months (yes)
Cocaine (powder) Age of onset 20.3 (6.7) 4 (4.3%)
Used in the last 12 months (yes)
Crack cocaine Age of onset 28.0 (12.8) 1 (1.1%)
Used in the last 12 months (yes)
Cannabis Age of onset 14.7 (2.5) 14 (15.1%)
Used in the last 12 months (yes)
Ecstasy Age of onset 16.3 (1.7) 1 (1.1%)
Used in the last 12 months (yes)
Tobacco Age of onset 14.1 (3.3) 58 (62.4%)
Used in the last 12 months (yes)
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of problems reported in PSYCHLOPS was 3 months to 1 year. In this sample, the
PSYCHLOPS problem of the longest duration was 1 to 5 years.
Internal Reliability of PQ and PSYCHLOPS Mean Scores
Both individualised measures showed good internal reliability, with alpha scores for PQ of .79
(mean) and for PSYCHLOPS .72 (Table 4).
Convergent Validity of PQ and PSYCHLOPS vs. Standardised Outcome Measures
Table 5 shows the correlation matrix between the five instruments. We found a weak and
significant convergence between PQ and PSYCHLOPS (r = .28) total scores. Correlations
between PQ and PSYCHLOPS problem scores were similar when self-completed (r = .25) or
when researcher administered (r = .25). The correlations between PQ and the total scores of
CORE-OM, PHQ-9 and TOP (psychological health) were weak at .27, .22 and .21 respectively
(see Table 5). In contrast, correlations between CORE-OM, PHQ-9 and TOP (psychological
health) with PSYCHLOPS were moderate at .50, .39 and .40, respectively.
Association Between PQ/PSYCHLOPS Scores and Demographic and Clinical Variables
Socio-Demographic Data There were no significant differences in PQ and PSYCHLOPS
scores according to gender, educational level, type of accommodation and employment status.
No correlation was found between item severity and patient age.
Substance Use and Treatment History There was no significant correlation between age
when patients started to use certain substances and their distress scores on individualised
Table 3 Substance misuse treatment history
Substance misuse treatment history n (%)
First treatment episode 49 (52.7%)
Type of previous treatment Psychological treatment 15 (17.4%)
Opioid substitution treatment 7 (8.1%)
Alcohol dependence medication 11 (12.8%)
Inpatient therapeutic community 13 (15.1%)
Detoxification unit 17 (19.8%)
Self-help groups 4 (4.7%)
Table 4 Internal reliability (Cronbach’s alpha) of PQ and PSYCHLOPS
Cronbach’s alpha values
PQ PQ items 1–2 PQ items 1–3 PQ items 1–4 PQ items 1–5 Mean (SD)
.69 .75 .83 .88 .79 (.09)
PSYCHLOPS Problem items 1–2 Problem + functioning items 1–3
(individualised component)
All items 1–4 (individualised items
+ standardised item)
.42 .69 .72
In PQ, item #1 corresponds to the first item in the PQ item list, i.e. the item identified by the patient as being the
problem he/she is most concerned about; item #2 is the second problem that most concerns the patient, etc.
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outcome measures. PQ and PSYCHLOPS score correlations with age of first substance misuse
for alcohol were r = .11, p = .33; r = .27, p = .06 (respectively) and for tobacco were r = .01,
p = .95; r = .02, p = .89 (respectively); numbers were too small to determine age correlations
for other substances (see Table 2).
Patients who had received previous treatment for substance misuse were more likely to
report a higher level of psychological distress both in PQ (t (90) = − 1.9, p < .05) and
PSYCHLOPS (t (56) = − 2.5, p < .02). Regarding the type of treatments received, patients
with previous psychological outpatient treatment (t (50) = 2.0, p < .04) and in therapeutic
communities (t (50) = 2.4, p < .02) had significantly higher problem scores in PSYCHLOPS
than those who did not. These effects were not observed in PQ. There were no significant
differences in mean scores of PQ and PSYCHLOPS problems comparing those receiving and
not receiving the remaining treatment modalities.
Mode of Administration PSYCHLOPS scores were significantly higher among those who
completed free-text descriptive items about problems in addition to scoring these items (t
(84) = 2.5, p < .01) and functioning (t (56) = 2.4, p < .02) in self-completed format.
Order of Instrument Administration There were no significant differences in mean total
severity scores relating to the order of individualised instrument completion. Comparing the
sequence of administration for PSYCHLOPS, the ANOVA F value = .32, p = .81; for PQ,
F = .71, p = .55.
Discussion
Previous findings have demonstrated the importance of PQ and PSYCHLOPS as sources of
qualitative, personalised information about patients undergoing treatment for substance misuse
(Alves et al. 2018). The present study adds to that body of literature by providing estimates
Table 5 Convergent validity of PQ and PSYCHLOPS with CORE-OM, PHQ-9 and TOP
Measures Domains PQ (n = 92) PSYCHLOPS (n = 58)
Problems Functioning Well-being Total
PSYCHLOPS Problems .35**
Functioning .23 .53**
Well-being .17 .39** .27*
Total score .28** .89** .73** .70**
CORE-OM Problems .31** .39** .38** .49** .48**
Functioning .12 .20 .31* .53** .39**
Well-being .30** .41** .35** .52** .49**
Risk .19 .32** .16 .37** .37**
Total score .27** .38** .37** .54** .50**
PHQ-9 .22* .39** .28* .52** .39**
TOP Psychological health − .21 − .33** − .12 − .60** − .40**
Physical health − .12 − .15 − .01 − .26* − .07*
Quality of life − .24* − .30** − .30* − .48 − .44**
*p ≤ .05; **p ≤ .01
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about the practicability, reliability and validity of such individualised outcome measures in this
context.
Are Individualised Measures Feasible for Use in Substance Misuse Treatment?
We found that the administration of the whole evaluation protocol took approximately 30 min
(i.e. approximately half the typical duration of a clinical session). This meant that
individualised measures were completed relatively quickly, suggesting that adopting one or
other of these measures might not be a burden in real clinical settings. Replicating previous
findings in a primary care mental health setting (Ashworth et al. 2005), the completion rates of
individualised measures were above 90%, demonstrating high levels of patient acceptability
and comparable to completion rates of the standardised measures included in our study,
showing that both types of measures are equally received by patients. However, nearly half
our sample missed at least two responses in PSYCHLOPS, hindering the calculation of total
scores and raising concerns about its feasibility as a self-report instrument. This was a low
number in comparison with previous studies, where more than 90% of patients’ responses to
PSYCHLOPS allowed total score calculation (Ashworth et al. 2004, 2005, 2009). In other
studies, PSYCHLOPS has been administered as an interview measure, to ensure no missing
data in populations with literacy issues (Harper Shehadeh et al. 2019).
Regarding the mode of administration, although designed to be self-completed, almost half
the sample asked for PSYCHLOPS to be researcher administered. This may have been due to
low literacy skills, high levels of patient distress on entering treatment and patients may have
felt more supported by being able to talk about their problems during assessment (Harper
Shehadeh et al. 2019). Patients reported higher severity scores in the written format, implying
that they might feel less comfortable verbalising their distress or that responses may be
moderated by perceptions of social disapproved, or even illegal, behaviours. Although con-
tradictory, our results were consistent with Bowling’s observation (Bowling 2005) that
interviewer-based methods are likely to increase response accuracy, but self-report question-
naires may encourage the sharing of more sensitive information. Conversely, no difference
was observed between self-report or researcher administered scores on the standardised
measures CORE-OM and PHQ-9.
Overall, our findings indicate that PQ and PSYCHLOPS are practicable in substance
misuse treatment settings. Nearly all patients invited to participate in the study were motivated
to complete the individualised measures, even though not all responded to them in the
expected format. In particular, there were many patients requesting the instruments to be
administered verbally by the researcher. This suggests that, even when self-report measures
such as PSYCHLOPS are selected, researchers and clinicians may have to enhance their
interview skills to ensure that data collection is not negatively affected for patients requesting
assistance.
Do Individualised Measures Generate Robust Psychometric Data?
Both PQ and PSYCHLOPS elicited fewer items than when used in other clinical populations.
For instance, in Elliott et al. (2016), the mean number of items created across five samples of
patients in general mental health treatment was 10, compared with three items in the present
study. Similar findings were reported in the previous section, when we observed that patients
in our sample tended to omit PSYCHLOPS items more often than other samples (Ashworth
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et al. 2004, 2007, 2009). When combined, these results indicate that substance misuse patients
provide less information in individualised measures than other clinical populations. Further
research is needed to explore why this occurred. However, we hypothesise that being admitted
for a specialist treatment, targeting a specific behaviour, might have led patients to think that it
was inappropriate, or unnecessary, to disclose too much information about their lives. On the
other hand, item scores and mean problem duration were similar to those reported in previous
studies (Ashworth et al. 2005; Elliott et al. 2016), indicating that patients experience similar
levels of psychological distress as in other generalist mental health samples, emphasising the
importance of addressing psychological health in this population (Wanigaratne et al. 2005).
Concerning psychometric properties, our analyses revealed good internal reliability for PQ
and PSYCHLOPS in the context of substance misuse therapy. Such reliability values were
similar to those previously reported in Elliott et al. (2016) (.86) andAshworth et al. (2005) (.79).
On the other hand, the convergence between individualised and standardised outcomemeasures
was weak to moderate. This might reflect the diversity of problems experienced by our sample
of patients, often unrelated to health and including concerns such as housing or finances not
covered by the standardised comparators used (Alves et al. 2007, 2018). PSYCHLOPS
correlated more strongly with standardised measures than did PQ. This might be a feature of
the structural characteristics of PSYCHLOPS which is a hybrid instrument containing one
standardised well-being item which correlated more strongly with the standardised measures,
whilst PQ is a pure patient-generated instrument, only containing personalised items.
A weak correlation was found between the two individualised measures. This was expected
for several reasons: the different structures of PQ and PSYCHLOPS may have prompted
patients to respond differently to both measures; a previous study (Alves et al. 2018) had
already found that patients tend not to repeat items/problems when answering both instruments
as part of the same evaluation protocol. Moreover, the original self-report format of
PSYCHLOPS was altered to an interview format in approximately half of the sample.
Considering that the information provided in a questionnaire depends on its administration
mode (Bowling 2005), it is unknown how much PSYCHLOPS responses were affected by
researcher completion. It remains possible that differences also arose because these instru-
ments were measuring differing underlying constructs, in spite of both focussing on patient-
reported ‘problems’.
To sum up, even though individualised measures produce reliable measurements, their
weak to moderate correlation with standardised measures suggests that they should comple-
ment standardised instruments rather than being used alone. Combining individualised and
standardised measures has been suggested by authors working in other treatment contexts and
may enhance their potential for outcome measurement (Barkham 2016; Sales and Alves 2012;
Sales et al. 2014). As Möller (2009) put it, whilst standardised measures can objectively
quantify psychological constructs, individualised information is able to capture “distinctive
characteristics of individuals” (p. 2016), giving a more meaningful context to the numbers
obtained with standardised tools.
Which Individual or Treatment Characteristics May Influence PQ and PSYCHLOPS
Scores?
Patients with past experience of substance misuse treatment were more likely to present higher
distress in PQ and PSYCHLOPS, in comparison with those starting their first treatment
episode. On the one hand, relapse may be particularly associated with distress and disruptive
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situations; also, patients who dropped out of previous treatment episode(s) without a successful
therapeutic result may be more likely to have unresolved personal issues reported as problems
on the individualised measures. Ramos and Brown (2008) identified that, among substance
misusers, the main reasons leading to substance misuse and relapse are social situations,
coping with negative emotions and interpersonal conflicts. These types of concerns were
reported by the same sample in PQ and PSYCHLOPS (Alves et al. 2018), which is in line with
our findings.
Regarding the age of onset of drug use, our study was partly in line with the literature,
which has reported that the younger individuals start to use drugs, the more severe their drug-
related problems (Hser et al. 2007). In support of this was the negative correlation between age
of first use of cannabis and PQ; and first use of LSD and PSYCHLOPS. However, for crack
and LSD in PQ and ecstasy in PSYCHLOPS, the reverse was true. For these patients, it is
likely that other bio-psycho-social factors may have contributed for their dependence disorder,
reinforcing the importance of a multidimensional evaluation of clinical status (Alves et al.
2018). Divergence in total PQ and PSYCHLOPS scores according to age of first use for
different substances indicates that they may be measuring different aspects of patient distress.
Limitations
The main limitation of our study is that it has not included post-treatment scores. Contrasting
pre-post treatment data would allow an estimation of further psychometric parameters of PQ
and PSYCHLOPS, such as sensitivity to change and temporal structure. High sensitivity to
change is a central characteristic of patient-generated instruments and requires further evalu-
ation within the context of dependence disorders (Ashworth et al. 2009; Elliott et al. 2016).
Feasibility could be explored further by comparing patient and staff preferences for different
combinations of instruments. Further feasibility comparisons could be made between pre-
therapy and during-therapy administration of both patient-generated instruments since each
adopts a different format after the start of therapy, with PQ only rating severity and
PSYCHLOPS changing to a during-therapy version. We only collected the administration
time for the entire protocol. Separate times would have provided a better estimate of
individualised measures’ length and how they compare to their standardised counterparts.
Moreover, we did not evaluate the quality of the items produced by patients in PQ and
PSYCHLOPS which may have contributed to divergent results.
Conclusion
With this study, we have confirmed that individualised measures are feasible and reliable to
use as outcome measures in substance misuse treatment, in line with previous studies on the
psychometrics of PQ and PSYCHLOPS in other settings (Ashworth et al. 2005, 2009; Elliott
et al. 2016). Convergent validity between individualised and standardised measures was weak
to moderate, suggesting that standardised and individualised measures may be measuring
different aspects of patient distress.
A further finding was the weak correlation between PQ and PSYCHLOPS and the
variability of results produced by them, when in fact these measures were expected to
measure distress due to similar constructs—patient’s individual concerns. Researcher and
self-administered modes of completion may have influenced item generation, potentially
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leading to the differences between the scorings of PQ and PSYCHLOPS. The possibility
remains that the two individualised measures were measuring different aspects of patient
distress.
In summary, our study suggests that PQ and PSYCHLOPS contribute to the measurement
of patient distress in substance misuse treatment. Both individualised measures are reliable and
have high levels of patient acceptability. Low to moderate convergence with standardised
instruments suggests that optimal outcome measurement may involve combining
individualised and standardised measures since this may broaden the capture of underlying
constructs.
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